Navigation Links
sanofi-aventis: Strong Performance of Growth Platforms in Q1 2011
Date:4/28/2011

rowth Platformsmillions of eurosQ1 2011Change at constant exchange ratesEmerging Markets(1/2)2,386

-2.6%Emerging Markets excluding Diabetes, Vaccines, CHC, new products, and Animal Health

1,475+7.7%Diabetes1,113+10.5%Vaccines602-38.3%Consumer Health Care (CHC)712+40.3%New products(3)111-Animal Health594+11.5%Total Growth Platforms4,607+4.3%(1) World excluding the U.S. and Canada, Western Europe, Japan, Australia and New Zealand.

(2) Include Diabetes, Vaccines and Consumer Health Care and Animal Health sales generated in Emerging Markets;

(3) Multaq® and Jevtana®. Including Fluzone High Dose®  vaccine, new products accounted for euro 111 million in Q1 2011 Appendix 6: Business net income statementFirst-quarter 2011PharmaceuticalsVaccinesAnimal healthOtherGroup  TotalMillions of eurosQ1 2011  Q1 2010   % change

Q1 2011Q1 2010% change

  Q1 2011Q1 2010(1)  % change

Q1 2011Q1 2010 Q1 2011Q1 2010  % changeNet sales6,5836,441+2.2%602944(36.2%)594513+15.8%7,7797,898(1.5%)Other revenues

404

385

+4.9%

5

54

5

(20.0%)413

395

+4.6%Cost of sales

(1,927)

(1,725)

+11.7%

(268)

(300)

(10.7%)

(167)

(152)

+9.9%(2,362)

(2,177)

+8.5%As % of net sales

(29.3%)

(26.8%)(44.5%)

(31.8%)(28.1%)

(29.6%)(30.4%)

(27.6%)Gross profit5,0605,101(0.8%)339649(47.8%)431366+17.8%5,8306,116(4.7%)As % of net sales76.9%79.2%56.3%68.8%72.6%71.3%74.9%77.4%Research and development expenses

(940)

(993)

(5.3%)

(125)

(117)

+6.8%

(35)

(36)

(2.8%)(1,100)

<
'/>"/>

SOURCE sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
2. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
3. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
4. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
5. AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study
6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
7. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
8. SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
9. US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings
10. Groundbreaking American Journal of Play from Strong National Museum of Play(R) Premiers July 2008
11. Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of Mr. C Causes Major Interest in the Scientific Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015 Eisai Inc. announced today that regulatory ... States , European Union and Japan ... for eribulin, for the treatment of patients with inoperable ... for advanced or metastatic disease. These ... global Phase 3 clinical trial (Study 309), which met ...
(Date:7/30/2015)... 30, 2015 Future Market Insights ... "Continuous Glucose Monitoring Systems Market: Global Industry Analysis and ... the global continuous glucose monitoring systems market was valued ... to reach US$ 788.4 Mn by 2020, registering a ... 2020. Global continuous glucose monitoring systems market ...
(Date:7/30/2015)... , July 30, 2015  Medimetriks Pharmaceuticals, Inc. ... second Phase III clinical study for Ozenoxacin, a ... Medimetriks owns the exclusive U.S. rights to Ozenoxacin ... conducted at 44 centers with an emphasis on ... aged 2 months and older with a clinical ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... Cardiovascular Safety and Potential Benefits of Exenatide to be Prospectively ... June 8 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ... ) today announced results from a meta-analysis of cardiovascular (CV) ... with BYETTA(R) (exenatide) injection use compared to a pooled comparator ...
... Dose Optimization of Pre-Clinical Otelixizumab Surrogate , ... a biopharmaceutical company engaged in the discovery and ... presented results from a pre-clinical dose-optimization study conducted ... monoclonal antibody, otelixizumab, at the 69th Scientific Sessions ...
Cached Medicine Technology:Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 2Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 3Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 4Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 5Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 6Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association 2Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association 3
(Date:7/31/2015)... and Rockport, ME (PRWEB) , ... July 31, 2015 , ... The alarm was ringing. ... , Glancing out of the window, he recalled that his equipment was set up ... Street tower, he jumped out of bed. , The photo speaks for itself. Chatfield ...
(Date:7/31/2015)... ... July 31, 2015 , ... Awarded to only the Top 10 hair transplant ... they are the latest recipients of the Center of Clinical Excellence for ARTAS ... worldwide leaders in the science of hair transplant. , Parsa Mohebi Hair Restoration is ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... contributor for LeadingAge’s Center for Aging Services Technologies (CAST) Medication Management Technologies whitepaper. ... and post-acute care providers understand the benefits of using medication management technologies ...
(Date:7/31/2015)... GA (PRWEB) , ... July 31, 2015 , ... ... Practice, Pediatric Emergency Medicine Practice, and Hospital Medicine Practice, is pleased to announce ... in a mobile application format available on iPhones, iPads, and Android smartphones ...
(Date:7/31/2015)... ... July 31, 2015 , ... “ Crack’em ” was featured ... coolest technology products available to consumers. Amanda Forstrom, a technology expert and special reporter ... make less mess while cooking. , Cooking can be a very messy experience, especially ...
Breaking Medicine News(10 mins):Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 2Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 3Health News:Make Less Mess while Cooking with Crack’em 2
... Hair with MilkSAN CLEMENTE, Calif., May 4 Maintaining strong, ... including Latinas. So when a new product comes on ... hair, many ladies jump on the bandwagon. The beauty ... more on hair care products than other Americans, according to ...
... Quality, for Company,s Medical DevicesPITTSBURGH, May 4 ... ), manufacturers of noninvasive medical evaluation equipment used ... other disorders, said today that it has earned ... and services.Nystagmography is the recording and measurement of ...
... new safety regulations, , , MONDAY, May 4 (HealthDay News) -- ... a mother. , Last March, her 2-year-old son and ... dressed in the bathroom. , Stevenson heard a crash. She ... lying on top of her daughter. Her son, Michael, was ...
... team of researchers at The National Cancer Center Hospital in ... lung cancer resection surgery between 2000 and 2006. The study ... of Thoracic Oncology , the official journal of the International ... his team found that after classifying patients based on the ...
... Others Question the Continuing Use of Mercury , WASHINGTON, ... Consumers for Dental Choice and the Mercury Policy Project, ... DHR ) corporation to transition out of manufacturing mercury ... Hotel in Washington D.C. this Tuesday, May 5 at ...
... The medical director for the Los Angeles Jewish ... in the western United States, today shared the Home,s ... for and precautions to take as fear of swine ... are very similar to that of the flu bugs ...
Cached Medicine News:Health News:Better Hair Days With Milk 2Health News:Better Hair Days With Milk 3Health News:Neuro Kinetics Earns ISO 13485 Certification 2Health News:More Kids Being Hurt by Falling Furniture 2Health News:More Kids Being Hurt by Falling Furniture 3Health News:Shareholders Challenge Danaher/Kerr to Phase Out Mercury Tooth Fillings 2Health News:Medical Director of Renowned Los Angeles Jewish Home Offers Advice to Seniors on Avoiding Swine Flu 2
PTC-100 cycler with gold/silver block with Hot Bonnet heated lid, holds one 96-well V-plate or96x0.2ml tubes...
MBS 0.2 ml satellite block unit with height adjusting heated lid, 96 well standard block - holds 96 x 0.2ml tubes or 1 x 96 well plate (includes tube thermistor)...
PxE thermal Cycler. 0.2ml, 96 well block holds 96 tubes or 1 x 96 well plate. Adjustable height heated lid. Outstanding uniformity. Advanced control algorithms for reduced reaction times. User f...
... (PxE) is a licensed 96 well PCR machine, ... for money thermal cycling. It is built ... in manufacturing and retains a high level of ... products in the range. The combination of ...
Medicine Products: